share_log

BullFrog AI Holdings, Inc. Appoints Josh Blacher as Chief Financial Officer Following the Passing of Dane Saglio

BullFrog AI Holdings, Inc. Appoints Josh Blacher as Chief Financial Officer Following the Passing of Dane Saglio

BullFrog人工智能控股公司任命Josh Blacher为首席财务官,继Dane Saglio去世之后。
Quiver Quantitative ·  12/17 16:41

BullFrog AI appoints Josh Blacher as CFO, following the passing of former CFO Dane Saglio.

BullFrog AI任命Josh Blacher为首席财务官,继前首席财务官Dane Saglio去世之后。

Quiver AI Summary

Quiver AI 概要

BullFrog AI Holdings, Inc. has announced the appointment of Josh Blacher as Chief Financial Officer following the passing of former CFO Dane Saglio. CEO Vin Singh expressed gratitude for Saglio's contributions and highlighted Blacher's extensive experience in financial strategy and corporate governance, important for carrying on Saglio's legacy. Blacher, who has over 20 years of experience in strategic finance within the life sciences and biotech sectors, previously served as CFO for several companies and has held senior positions at Teva Pharmaceuticals. In his new role, Blacher will focus on strengthening the company's financial operations and supporting its strategic initiatives.

BullFrog AI Holdings, Inc.已宣布任命Josh Blacher为首席财务官,此举是在前首席财务官Dane Saglio去世后进行的。首席执行官Vin Singh对Saglio的贡献表示感谢,并强调Blacher在金融策略和公司治理方面的广泛经验,这对延续Saglio的遗产非常重要。Blacher在生命科学和生物技术领域的战略金融方面拥有超过20年的经验,曾担任多家公司的首席财务官,并在Teva制药公司担任高级职位。在新角色中,Blacher将专注于增强公司的财务运营并支持其战略举措。

Potential Positives

潜在的积极因素

  • Appointment of Josh Blacher as Chief Financial Officer, bringing over two decades of experience in strategic finance and corporate development for life sciences and biotech companies.
  • Mr. Blacher's expertise in financial stewardship, operations, and capital raising is expected to enhance the company's balance sheet strength and support its strategic initiatives.
  • The press release acknowledges the contributions of former CFO Dane Saglio, creating a narrative of continuity in leadership amidst the transition.
  • 任命Josh Blacher为首席财务官,带来了超过二十年的战略金融和公司发展经验,专注于生命科学和生物技术公司。
  • Blacher先生在财务管理、运营和资本筹措方面的专业知识预计将增强公司的资产负债表实力,并支持其战略举措。
  • 新闻稿承认了前首席财务官Dane Saglio的贡献,创造了领导层在过渡时期的连续性叙述。

Potential Negatives

潜在负面因素

  • The press release highlights the untimely passing of the former CFO, which could raise concerns about the company's stability and the impact of leadership changes on its operations.
  • The need to appoint a new CFO at this moment may indicate potential issues related to financial governance and continuity in leadership.
  • The mention of forward-looking statements contains caveats about risks and uncertainties, suggesting potential challenges in achieving the company's projected performance and growth metrics.
  • 新闻稿强调了前首席财务官的不幸去世,这可能引发人们对公司稳定性以及领导层变动对业务运营影响的担忧。
  • 此时需要任命新首席财务官,可能表明在财务治理和领导层连续性方面存在潜在问题。
  • 提到前瞻性声明时包含关于风险和不确定性的警告,暗示在实现公司预期表现和增长指标方面可能面临挑战。

FAQ

常见问题

Who has been appointed as the new CFO of BullFrog AI?

谁被任命为BullFrog AI的新首席财务官?

Josh Blacher has been appointed as the Chief Financial Officer of BullFrog AI, effective immediately.

Josh Blacher已被任命为BullFrog AI的首席财务官,立即生效。

What experience does Josh Blacher bring to BullFrog AI?

Josh Blacher为BullFrog AI带来了什么经验?

Josh Blacher brings over two decades of experience in strategic finance and corporate development within the life science and biotech sectors.

Josh Blacher在生命科学和生物技术领域拥有超过二十年的战略财务和企业发展的经验。

What position did Dane Saglio hold at BullFrog AI before his passing?

丹·萨里奥在BullFrog AI去世前担任什么职位?

Dane Saglio served as the Chief Financial Officer (CFO) of BullFrog AI prior to his untimely passing.

丹·萨里奥在去世前担任BullFrog AI的首席财务官。

How does BullFrog AI utilize artificial intelligence in drug development?

BullFrog AI如何在药物开发中利用人工智能?

BullFrog AI employs causal AI and its proprietary bfLEAP platform to analyze complex biological data for improving drug discovery and development.

BullFrog AI利用因果AI和其专有的bfLEAP平台分析复杂的生物数据,以提高药物发现和开发的效率。

What is the mission of BullFrog AI?

BullFrog AI的使命是什么?

The mission of BullFrog AI is to revolutionize drug development and reduce failure rates in clinical trials through innovative technology.

BullFrog AI的使命是通过创新技术彻底改变药物开发并降低临床试验中的失败率。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免责声明:这是由GlobeNewswire分发的新闻稿的人工智能生成摘要。用于总结这份稿件的模型可能会出错。请在这里查看完整发布。


$BFRG Hedge Fund Activity

$BFRG对冲基金活动

We have seen 1 institutional investors add shares of $BFRG stock to their portfolio, and 9 decrease their positions in their most recent quarter.

我们看到1家机构投资者在最近一个季度增持了$BFRG股票的股份,9家则减持了他们的持仓。

Here are some of the largest recent moves:

以下是最近的一些重大变动:

  • VIRTU FINANCIAL LLC removed 27,189 shares (-100.0%) from their portfolio in Q3 2024
  • RENAISSANCE TECHNOLOGIES LLC removed 19,800 shares (-100.0%) from their portfolio in Q3 2024
  • XTX TOPCO LTD removed 8,263 shares (-44.5%) from their portfolio in Q3 2024
  • GEODE CAPITAL MANAGEMENT, LLC added 8,221 shares (+29.6%) to their portfolio in Q3 2024
  • TOWER RESEARCH CAPITAL LLC (TRC) removed 5,270 shares (-85.6%) from their portfolio in Q3 2024
  • UBS GROUP AG removed 3,515 shares (-100.0%) from their portfolio in Q3 2024
  • FORTEM FINANCIAL GROUP, LLC removed 1,900 shares (-3.6%) from their portfolio in Q3 2024
  • Virtu金融 LLC 在2024年第三季度从他们的投资组合中剔除了27,189股(-100.0%)。
  • Renaissance Technologies LLC 在2024年第三季度从他们的投资组合中剔除了19,800股(-100.0%)。
  • XTX Topco Ltd在2024年第三季度从他们的投资组合中剔除了8,263股(-44.5%)。
  • Geode Capital Management LLC在2024年第三季度为他们的投资组合增持了8,221股(+29.6%)。
  • 塔架研究资本 LLC (TRC)在2024年第三季度从他们的投资组合中剔除了5,270股(-85.6%)。
  • 瑞银集团 AG在2024年第三季度从他们的投资组合中剔除了3,515股(-100.0%)。
  • FORTEm金融集团,LLC 在2024年第3季度从其投资组合中减持了1,900股(-3.6%)。

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要跟踪对冲基金的股票投资组合,请查看Quiver Quantitative的机构持有情况仪表。

Full Release

完整发布



GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the appointment of Josh Blacher as its Chief Financial Officer (CFO), effective immediately. This appointment comes in the wake of the untimely passing of Dane Saglio, BullFrog AI's former CFO, who recently lost his battle with cancer.


盖瑟斯堡,马里兰州,2024年12月17日(全球新闻)—— BullFrog AI Holdings, Inc.(纳斯达克:BFRG;BFRGW)("BullFrog AI"或"公司")是一家利用人工智能(AI)和机器学习推动药物和生物制品成功开发的科技驱动药物开发公司,今天宣布任命Josh Blacher为首席财务官,立即生效。这一任命是在BullFrog AI原首席财务官Dane Saglio不幸去世后做出的,他最近与癌症进行了斗争。



"Dane's contributions to BullFrog AI were immeasurable. Beyond his exceptional expertise and dedication, Dane was a trusted advisor and a cherished friend. His wisdom, humility, and steadfast commitment to our mission will be deeply missed," said Vin Singh, CEO of BullFrog AI. "At the same time, we are grateful to welcome Josh to our team at this pivotal moment. Josh's extensive experience and leadership in financial strategy and corporate governance will be invaluable as we carry forward Dane's legacy and advance our mission to revolutionize drug development."


“Dane对BullFrog AI的贡献是无法估量的。除了他卓越的专业技能和奉献精神,Dane还是一位值得信赖的顾问和深受爱戴的朋友。他的智慧、谦逊以及对我们使命的坚定承诺将被深深怀念,”BullFrog AI首席执行官Vin Singh说道。“同时,我们也感激在这个关键时刻欢迎Josh加入我们的团队。Josh在财务策略和公司治理方面的丰富经验和领导才能将在我们推进Dane的遗产和提升我们药物开发革命化使命的过程中发挥重要作用。”



Mr. Blacher, with more than two decades of experience in strategic finance and corporate development for life science and biotech companies, brings to BullFrog AI a proven track record in financial stewardship, capital raising, operations and profitability, and deal making. He has successfully overseen SEC reporting and investor relations for both private and publicly traded companies. Most recently, he has served as CFO for Predictive Oncology, Rampart Bioscience, Excision BioTherapeutics, and has previously held senior roles at Teva Pharmaceuticals, among others. Mr. Blacher earned his BA in Economics from Yeshiva University and an MBA in Finance from Columbia Business School.


Blacher先生在战略财务和生命科学及生物科技公司的企业发展的领域拥有超过二十年的经验,为BullFrog AI带来了财务管理、资本筹集、运营和盈利能力以及交易谈判方面的成功记录。他成功监督了私营和上市公司的证券交易委员会报告和投资者关系。最近,他担任了Predictive Oncology、Rampart Bioscience、Excision BioTherapeutics的首席财务官,并在Teva制药等公司担任过高级职务。Blacher先生获得了耶西瓦大学的经济学学士学位和哥伦比亚商学院的金融MBA。



In assuming the role of CFO, Mr. Blacher will build on the foundation laid by Mr. Saglio, focusing on enhancing the Company's balance sheet strength, financial operations and supporting its strategic initiatives.


在担任首席财务官的过程中,Blacher先生将建立在Saglio先生奠定的基础上,专注于增强公司的资产负债表实力、财务运营,并支持公司的战略计划。




About BullFrog AI



关于BullFrog AI



BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.


BullFrog AI利用人工智能和机器学习推动药物发现和开发。通过与领先的研究机构合作,BullFrog AI将因果AI与其专有的bfLEAP平台相结合,以分析复杂的生物数据,旨在简化治疗开发并降低临床试验中的失败率。



For more information visit BullFrog AI at:



.


欲了解更多信息,请访问BullFrog AI:



.




Safe Harbor Statement



安全港声明



This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "could," "will," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.


本新闻稿包含前瞻性陈述。我们基于对未来事件的预期和预测来制定这些前瞻性陈述,这些预期和预测来源于我们目前可获取的信息。这些前瞻性陈述涉及未来事件或我们的未来表现,包括:我们的财务表现和预测;我们的营业收入和收益的增长;以及我们的业务前景和机会。您可以通过那些不具有历史性质的陈述来识别前瞻性陈述,特别是那些使用"可能"、"应该"、"会"、"将"、"期望"、"预期"、"考虑"、"估计"、"相信"、"计划"、"预测"、"预言"、"潜在"或"希望"等术语或这些术语的否定形式。评估这些前瞻性陈述时,您应该考虑各种因素,包括:我们改变公司方向的能力;我们跟上新技术和变化的市场需求的能力;以及我们业务的竞争环境。这些以及其他因素可能导致我们的实际结果与任何前瞻性陈述存在重大差异。前瞻性陈述仅仅是预测。本新闻稿中讨论的前瞻性事件以及我们或我们的代表随时发出的其他陈述,可能不会发生,实际事件和结果可能存在重大差异,并且受关于我们的风险、不确定性和假设的影响。我们没有义务公开更新或修订任何前瞻性陈述,无论是由于不确定性和假设的结果,还是本新闻稿中讨论的前瞻性事件以及我们或我们的代表随时发出的其他陈述可能不会发生。




Contact:



联系:



Dave Gentry
RedChip Companies, Inc.
1-407-644-4256

BFRG@redchip.com


戴夫·根特里
红芯公司
1-407-644-4256

BFRG@redchip.com



声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发